The DOI matches its Crossref record; 289 of the 289 references it cites were found in a registry or an index.
Ten years of anti-vascular endothelial growth factor therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“…VEGFA inhibition results in the apoptosis of endothelial cells that are not covered by pericytes and reduces the abnormal tortuosity and hyperpermeability of the tumour vasculature (‘normalization’), thus reducing tumour interstitial pressure and enhancing the delivery of cytotoxic agents 76,77 .”
Background
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
Self-citationAptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Functional morphology of the blood–brain barrier in health and disease
Liebner, S., Dijkhuizen, R. M., Reiss, Y., Plate, K. H., Agalliu, D., & Constantin, G. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1815-1 · Cited by 872
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
“Notwithstanding the favorable effects of these inhibitors in some patients, they improve progression-free survival and quality of life, but are unfortunately short-lived and modestly influence overall survival in most patients (12, 15, 16).”
BackgroundNext generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Cardiovascular Toxic Effects of Targeted Cancer Therapies
Moslehi, J. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1100265 · Cited by 635
Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies
Claesson-Welsh, L., Dejana, E., & McDonald, D. M. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.11.006 · Cited by 631
Therapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2
Peach, C. J., Mignone, V. W., Arruda, M. A., Alcobia, D. C., Hill, S. J., Kilpatrick, L. E., & Woolard, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041264 · Cited by 512
Current Advances in Chitosan Nanoparticles Based Drug Delivery and Targeting
Garg, U., Chauhan, S., Nagaich, U., & Jain, N. (2019) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2019.023 · Cited by 505
Circular Noncoding RNA HIPK3 Mediates Retinal Vascular Dysfunction in Diabetes Mellitus
Shan, K., Liu, C., Liu, B.-H., Chen, X., Dong, R., Liu, X., Zhang, Y.-Y., Liu, B., Zhang, S.-J., Wang, J.-J., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029004 · Cited by 504
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role
Wang, X., Bove, A. M., Simone, G., & Ma, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.599281 · Cited by 442
Zhou, J., Li, M., Hou, Y., Luo, Z., Chen, Q., Cao, H., Huo, R., Xue, C., Sutrisno, L., Hao, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00309 · Cited by 424
Vascular endothelial growth factor: a neurovascular target in neurological diseases
Lange, C., Storkebaum, E., de Almodóvar, C. R., Dewerchin, M., & Carmeliet, P. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.88 · Cited by 382
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab
Monés, J., Srivastava, S. K., Jaffe, G. J., Tadayoni, R., Albini, T. A., Kaiser, P. K., Holz, F. G., Korobelnik, J.-F., Kim, I. K., Pruente, C., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.11.011 · Cited by 351
Platelets in wound healing and regenerative medicine
Etulain, J. (2018) · Platelets · doi:10.1080/09537104.2018.1430357 · Cited by 354
VEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer
Zhao, J., Du, P., Cui, P., Qin, Y., Hu, C., Wu, J., Zhou, Z., Zhang, W., Qin, L., & Huang, G. (2018) · Oncogene · doi:10.1038/s41388-018-0250-z · Cited by 342
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Le, X., Nilsson, M., Goldman, J., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt-Moller, B., Wolff, K., Visseren-Grul, C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.006 · Cited by 339
Pandey, A. K., Singhi, E. K., Arroyo, J. P., Ikizler, T. A., Gould, E. R., Brown, J., Beckman, J. A., Harrison, D. G., & Moslehi, J. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10271 · Cited by 338
Vascular endothelial growth factor signaling in development and disease
Karaman, S., Leppänen, V.-M., & Alitalo, K. (2018) · Development · doi:10.1242/dev.151019 · Cited by 335
The Role of Inflammation in Age-Related Macular Degeneration
Tan, W., Zou, J., Yoshida, S., Jiang, B., & Zhou, Y. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.49890 · Cited by 311
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Self-citationRe-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Saxena, M., & Bhardwaj, N. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.007 · Cited by 305
Joussen, A. M., Ricci, F., Paris, L. P., Korn, C., Quezada-Ruiz, C., & Zarbin, M. (2021) · Eye · doi:10.1038/s41433-020-01377-x · Cited by 290
Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain
Hamilton, J. L., Nagao, M., Levine, B. R., Chen, D., Olsen, B. R., & Im, H.-J. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2828 · Cited by 287
Hack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
Sahni, J., Patel, S. S., Dugel, P. U., Khanani, A. M., Jhaveri, C. D., Wykoff, C. C., Hershberger, V. S., Pauly-Evers, M., Sadikhov, S., Szczesny, P., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.023 · Cited by 285
Lu, J., Wang, Y.-H., Yoon, C., Huang, X.-Y., Xu, Y., Xie, J.-W., Wang, J.-B., Lin, J.-X., Chen, Q.-Y., Cao, L.-L., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.038 · Cited by 271
Roskoski, R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.010 · Cited by 260
Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases
Fallah, A., Sadeghinia, A., Kahroba, H., Samadi, A., Heidari, H. R., Bradaran, B., Zeinali, S., & Molavi, O. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.022 · Cited by 259
Determinants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 258
Pathophysiology of diabetic retinopathy: The old and the new
Kusuhara, S., Fukushima, Y., Ogura, S., Inoue, N., & Uemura, A. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0182 · Cited by 250
Trial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Kim, C. G., Jang, M., Kim, Y., Leem, G., Kim, K. H., Lee, H., Kim, T.-S., Choi, S. J., Kim, H.-D., Han, J. W., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aay0555 · Cited by 245
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Khanani, A. M., Patel, S. S., Ferrone, P. J., Osborne, A., Sahni, J., Grzeschik, S., Basu, K., Ehrlich, J. S., Haskova, Z., & Dugel, P. U. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2699 · Cited by 183
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
Sahni, J., Dugel, P. U., Patel, S. S., Chittum, M. E., Berger, B., del Valle Rubido, M., Sadikhov, S., Szczesny, P., Schwab, D., Nogoceke, E., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2685 · Cited by 129
Regulation and Function of Matrix Metalloproteinase-13 in Cancer Progression and Metastasis
Li, S., Pritchard, D. M., & Yu, L.-G. (2022) · Cancers · doi:10.3390/cancers14133263 · Cited by 82
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Hypoxia-inducible factor 2α: a novel target in gliomas
Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0163 · Cited by 40
Lv, H., Xu, R., Xie, X., Liang, Q., Yuan, W., Xia, Y., Ao, X., Tan, S., Zhao, L., Wu, J., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.06.043 · Cited by 38
Krüger, K., Silwal-Pandit, L., Wik, E., Straume, O., Stefansson, I. M., Borgen, E., Garred, Ø., Naume, B., Engebraaten, O., & Akslen, L. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-81914-0 · Cited by 32
Fu, C., Tyagi, R., Chin, A. C., Rojas, T., Li, R.-J., Guha, P., Bernstein, I. A., Rao, F., Xu, R., Cha, J. Y., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.311983 · Cited by 28
Metadata
- Authors
- Ferrara, N., & Adamis, A. P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2016-01-18
- Volume
- 15
- Issue
- 6
- Pages
- 385-403
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2293809486
- Cited by
- 1,030
- References
- 289
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.